Clinical trial NCT00109798: Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
Official title: Phase II Trial of Salvage Chemotherapy With Temozolomide in Combination With Topotecan for Primary CNS Lymphoma
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Central Nervous System Tumors
Lymphoma
Keywords: primary central nervous system non-Hodgkin lymphoma
primary central nervous system Hodgkin lymphoma
Lead sponsor: The Methodist Hospital Research Institute
Sponsor class: OTHER
Collaborators: name: Baylor College of Medicine
First posted: 2005-05-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: Drugs used in chemotherapy, such as temozolomide and topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving temozolomide together with topotecan works in treating patients with primary CNS lymphoma.

Detailed description: OBJECTIVES:

Primary

* Determine the complete radiologic response rate in patients with primary CNS lymphoma treated with salvage chemotherapy comprising temozolomide and topotecan.

Secondary

* Determine the median and failure-free survival of patients treated with this regimen.
* Determine the toxicity of this regimen in these patients.
* Determine the overall response rate in patients treated with this regimen.

OUTLINE: This is an open-label study.

Patients receive oral temozolomide once daily on days 1-5 and topotecan IV over 30 minutes once daily on days 2-6. Treatment repeats every 28 days for 6-8 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 6-25 patients will be accrued for this study.

Eligibility criteria: Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed primary CNS lymphoma at initial diagnosis
* Measurable tumor by radiography
* Failed\* OR is not a candidate for first-line high-dose systemic methotrexate-based chemotherapy with or without radiotherapy NOTE: \*Failure is defined as relapse, progression, or failure to achieve a complete response

PATIENT CHARACTERISTICS:

Age

* 18 and over

Performance status

* Karnofsky 50-100%

Life expectancy

* Not specified

Hematopoietic

* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 9 g/dL

Hepatic

* SGOT and SGPT ≤ 3 times upper limit of normal
* Bilirubin ≤ 2.0 mg/dL

Renal

* Creatinine clearance \> 40 mL/min

Other

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative
* No known allergy to temozolomide or topotecan
* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer in complete remission
* No other major medical illness or psychiatric impairment that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

* No concurrent prophylactic growth factors

Chemotherapy

* See Disease Characteristics
* At least 6 weeks since prior nitrosoureas
* At least 2 weeks since prior methotrexate

Endocrine therapy

* Not specified

Radiotherapy

* See Disease Characteristics

Surgery

* Not specified

Other

* Recovered from all prior therapy
* At least 4 weeks since prior non-nitrosourea cytotoxic drugs (except methotrexate)
* At least 4 weeks since prior systemic investigational agents
* At least 2 weeks since prior non-cytotoxic antitumor drugs
* No other concurrent antitumor therapy

EXCLUSION CRITERA

1. Patients who are pregnant or breastfeeding, or females of childbearing potential not using adequate contraception.
2. Known allergy to temozolomide or topotecan.
3. Severe vomiting or other inability to administer medications orally.
4. Major medical illnesses or psychiatric impairment that in the investigator's opinion will prevent administration or completion of the protocol therapy and/or will interfere with follow-up.

Primary outcomes:
measure: Rate of complete radiologic response (CR)
timeFrame: July 2006
Secondary outcomes:
measure: Median overall survival
timeFrame: July 2006
measure: Failure-free survival
timeFrame: July 2006
measure: Toxicity
timeFrame: July 2006
measure: Overall response rate (CR and partial response)
timeFrame: July 2006
Other outcomes:
Locations:
Study officials:
affiliation: Baylor College of Medicine
name: Pamela Z. New, MD
role: STUDY_CHAIR
References: